Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2019

View Archived Issues

Size matters in RNA-seq analyses

Anti-Siglec-15 monoclonal antibody NC-318 well tolerated and active in first-in-human study

IND approval and patent application for the first-ever liquid formulation of topiramate

Results presented from ongoing phase I/II study of IDE-196

ZGN-1345 demonstrates promise in preclinical models of NASH and HCC

Phase II data presented for ziltivekimab in hemodialysis patients

SARA as a potential new therapeutic target in human chronic kidney disease

New FFA1 agonist derived from an old scaffold shows potential for treatment of type 2 diabetes

Gut microbiota dysbiosis promotes neuroinflammation in Alzheimer's disease progression

Discovery of new potent NS4B inhibitor, JMX-0254

Rat homologue of FX-201 decreases incidence and severity of osteoarthritis-related lesions

TLN1 gene mutations linked to human nephrotic syndrome

Redox repositioning reaps benefits in TB treatment

Truncated ACE2 fusion protein targets RAS overactivity in renal diseases

Data on peripheral immune responses to selgantolimod from phase II study in HBV reported

L-FABP levels correlated with sarcopenia measures in diabetic kidney disease

Eternity Bioscience patents RORC antagonists

Bristol-Myers Squibb discloses new UFO and MERTK inhibitors

Rigel Pharmaceuticals synthesizes RIPK1 inhibitors

Enanta Pharmaceuticals describes new MAP3K5 inhibitors

Kinnate Biopharma patents CDK inhibitors

FDA approves Givlaari for acute hepatic porphyria

New phase I study evaluates bispecific PSMAxCD3 antibody CC-1 in CRPC

Arcutis begins phase II study of ARQ-154 foam for seborrheic dermatitis

Phoenix Molecular initiates first-in-human study of PMD-026 in advanced breast cancer

FDA approves phase I/II trial of Hope's adipose-derived mesenchymal stem cells for Alzheimer's

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...